ADmit Therapeutics presents the MAP-AD Test at the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)

Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the Neurogenetics Conference organized by MANLAB within the framework of the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026). Dr. Carla Trapero will present the MAP-AD Test, the only regulatory-approved blood-based prognostic test (IVDR – EU 2017/746) that predicts progression to Alzheimer’s dementia in patients with mild cognitive impairment

For more information: https://diagnosticsnews.com/especialidades-medicas/jornadas-de-neurogenetica-manlab-marite-garimaldi-anticipa-los-avances-en-neurogenetica-y-alzheimer-que-manlab-presentara-en-calilab-2026